Arkadios Wealth Advisors Buys 9,404 Shares of Omnicell, Inc. (NASDAQ:OMCL)

Arkadios Wealth Advisors raised its stake in Omnicell, Inc. (NASDAQ:OMCL) by 27.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 43,454 shares of the company’s stock after buying an additional 9,404 shares during the quarter. Arkadios Wealth Advisors owned about 0.09% of Omnicell worth $1,935,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of OMCL. Dimensional Fund Advisors LP lifted its stake in Omnicell by 0.3% in the second quarter. Dimensional Fund Advisors LP now owns 1,180,503 shares of the company’s stock valued at $31,955,000 after buying an additional 3,570 shares in the last quarter. Renaissance Technologies LLC lifted its position in shares of Omnicell by 83.4% in the second quarter. Renaissance Technologies LLC now owns 131,300 shares of the company’s stock worth $3,554,000 after purchasing an additional 59,700 shares in the last quarter. Hsbc Holdings PLC lifted its position in shares of Omnicell by 34.8% in the second quarter. Hsbc Holdings PLC now owns 37,685 shares of the company’s stock worth $1,010,000 after purchasing an additional 9,730 shares in the last quarter. Inspire Investing LLC lifted its position in shares of Omnicell by 7.5% in the second quarter. Inspire Investing LLC now owns 13,024 shares of the company’s stock worth $353,000 after purchasing an additional 913 shares in the last quarter. Finally, Canada Pension Plan Investment Board lifted its position in shares of Omnicell by 5.3% in the second quarter. Canada Pension Plan Investment Board now owns 90,800 shares of the company’s stock worth $2,458,000 after purchasing an additional 4,600 shares in the last quarter. Institutional investors own 97.70% of the company’s stock.

Insider Buying and Selling at Omnicell

In other Omnicell news, Director Mark W. Parrish sold 12,000 shares of the company’s stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $47.30, for a total value of $567,600.00. Following the transaction, the director now directly owns 58,427 shares in the company, valued at $2,763,597.10. The trade was a 17.04 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 2.64% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on OMCL. Benchmark reissued a “buy” rating and issued a $48.00 price objective on shares of Omnicell in a research report on Wednesday, October 9th. Barclays boosted their price objective on shares of Omnicell from $39.00 to $58.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 31st. Craig Hallum boosted their price objective on shares of Omnicell from $45.00 to $64.00 and gave the stock a “buy” rating in a research report on Thursday, October 31st. StockNews.com lowered shares of Omnicell from a “buy” rating to a “hold” rating in a research report on Tuesday, December 10th. Finally, Bank of America lowered their target price on shares of Omnicell from $54.00 to $46.00 and set a “neutral” rating on the stock in a report on Monday, January 6th. Five investment analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $50.00.

Omnicell Trading Up 1.0 %

Shares of OMCL opened at $42.57 on Friday. The company has a market cap of $1.97 billion, a price-to-earnings ratio of -109.15, a PEG ratio of 29.49 and a beta of 0.78. Omnicell, Inc. has a 1-year low of $25.12 and a 1-year high of $55.74. The company’s fifty day simple moving average is $45.06 and its 200 day simple moving average is $41.68.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.